DK0726778T3 - Oral administration af kemisk modificerede proteiner - Google Patents

Oral administration af kemisk modificerede proteiner

Info

Publication number
DK0726778T3
DK0726778T3 DK95911690T DK95911690T DK0726778T3 DK 0726778 T3 DK0726778 T3 DK 0726778T3 DK 95911690 T DK95911690 T DK 95911690T DK 95911690 T DK95911690 T DK 95911690T DK 0726778 T3 DK0726778 T3 DK 0726778T3
Authority
DK
Denmark
Prior art keywords
chemically modified
oral administration
modified proteins
csf
pegylated
Prior art date
Application number
DK95911690T
Other languages
Danish (da)
English (en)
Inventor
Alan D Habberfield
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK0726778T3 publication Critical patent/DK0726778T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK95911690T 1994-02-08 1995-02-08 Oral administration af kemisk modificerede proteiner DK0726778T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19418794A 1994-02-08 1994-02-08
US37912195A 1995-02-01 1995-02-01
PCT/US1995/001752 WO1995021629A1 (en) 1994-02-08 1995-02-08 Oral delivery of chemically modified proteins

Publications (1)

Publication Number Publication Date
DK0726778T3 true DK0726778T3 (da) 2001-09-24

Family

ID=26889779

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00122148T DK1090645T3 (da) 1994-02-08 1995-02-08 Oral tilförsel af kemisk modificerede proteiner
DK95911690T DK0726778T3 (da) 1994-02-08 1995-02-08 Oral administration af kemisk modificerede proteiner

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK00122148T DK1090645T3 (da) 1994-02-08 1995-02-08 Oral tilförsel af kemisk modificerede proteiner

Country Status (12)

Country Link
US (2) US20020099001A1 (xx)
EP (2) EP0726778B1 (xx)
AT (2) ATE311908T1 (xx)
AU (1) AU1916295A (xx)
DE (2) DE69534676T2 (xx)
DK (2) DK1090645T3 (xx)
ES (2) ES2251924T3 (xx)
GR (1) GR3036625T3 (xx)
HK (1) HK1036214A1 (xx)
IL (1) IL112583A0 (xx)
PT (1) PT726778E (xx)
WO (1) WO1995021629A1 (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885567A (en) * 1993-10-22 1999-03-23 University Of Connecticut Treatment of infection in fowl by oral administration of avian interferon proteins
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
EE05201B1 (et) 1998-10-16 2009-08-17 Biogen Idec Ma Inc. Glkoslitud interferoon-beeta, selle kasutamine ja seda sisaldav farmatseutiline kompositsioon, meetod interferoon-beeta-1a aktiivsuse pikendamiseks ja leiutisekohase valgu valmistamiseks
CA2343094A1 (en) 1998-10-16 2000-04-27 Biogen, Inc. Interferon-beta fusion proteins and uses
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
ATE435033T1 (de) 2000-01-10 2009-07-15 Maxygen Holdings Ltd G-csf konjugate
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
JP2006523683A (ja) * 2003-04-15 2006-10-19 オッパーバス・ホールディング・ビー・ブイ タンパク質及び／またはポリペプチド及びコロイド粒子を含む医薬組成物
US7834147B2 (en) 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
US7943179B2 (en) * 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
CA2586365A1 (en) 2004-11-05 2006-05-26 Northwestern University Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
JP4951527B2 (ja) 2005-01-10 2012-06-13 バイオジェネリックス アーゲー 糖ｐｅｇ化顆粒球コロニー刺激因子
AU2006254543A1 (en) 2005-06-01 2006-12-07 Maxygen Holdings Ltd. PEGylated G-CSF polypeptides and methods of producing same
KR100694994B1 (ko) 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
EP2197919B1 (en) 2007-08-27 2014-04-09 ratiopharm GmbH Liquid formulation of g-csf conjugate
WO2012018628A1 (en) 2010-07-26 2012-02-09 Board Of Regents, The University Of Texas System Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
US9974850B2 (en) 2013-01-25 2018-05-22 Board Of Regents, The University Of Texas System Immunogenic compositions and uses thereof
WO2018085495A2 (en) * 2016-11-02 2018-05-11 Board Of Regents, The University Of Texas System Dissolvable films and methods of their use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2792862B2 (ja) * 1988-07-30 1998-09-03 寛治 高田 経口腸溶製剤
WO1990006952A1 (en) * 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
DE69120141T2 (de) * 1990-03-28 1996-11-28 Shuji Kojima Polymerkombiniertes Arzneimittel zur Magenbehandlung und Verfahren zu dessen Herstellung
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US6565841B1 (en) * 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
FR2693907B1 (fr) * 1992-07-23 1994-09-02 Rhone Poulenc Rorer Sa Procédé d'administration de solutions de facteur de stimulation des colonies granulocytaires.
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods

Also Published As

Publication number Publication date
AU1916295A (en) 1995-08-29
US20030185795A1 (en) 2003-10-02
HK1036214A1 (en) 2001-12-28
DE69521880T2 (de) 2002-01-03
PT726778E (pt) 2001-12-28
ES2159630T3 (es) 2001-10-16
US20020099001A1 (en) 2002-07-25
EP1090645A2 (en) 2001-04-11
EP0726778B1 (en) 2001-07-25
GR3036625T3 (en) 2001-12-31
EP0726778A1 (en) 1996-08-21
EP1090645A3 (en) 2002-02-27
IL112583A0 (en) 1995-05-26
ES2251924T3 (es) 2006-05-16
WO1995021629A1 (en) 1995-08-17
DE69521880D1 (de) 2001-08-30
DK1090645T3 (da) 2006-03-27
ATE311908T1 (de) 2005-12-15
ATE203415T1 (de) 2001-08-15
EP1090645B1 (en) 2005-12-07
DE69534676D1 (de) 2006-01-12
DE69534676T2 (de) 2006-08-17

Similar Documents

Publication Publication Date Title
DK0726778T3 (da) Oral administration af kemisk modificerede proteiner
HK1245320A1 (zh) 治療缺陷α半乳糖苷酶A的藥物製劑
DK0733067T3 (da) N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
DK642587A (da) Insulinpraeparat
DK0644932T3 (da) Oprensede former af DNase
MA26488A1 (fr) Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
NZ504771A (en) IFNAR2/ INFcomplex for prolonging the in vivo effects of type I interferon (INF)
DE3773295D1 (de) Homogene rekombinante immun-interferon-fragmente und diese enthaltende pharmazeutische zusammensetzungen.
MA22343A1 (fr) Compositions type massepain, contenant du psyllium
OA07270A (fr) Dérivés N-(vinblastinoyl-23) d'acide aminés, leur préparation et leur application thérapeutique.
IT1243358B (it) Composizioni farmaceutiche per la somministrazione orale di irudina
DE69706657D1 (de) Natürliches menschliches alpha interferon enthaltende pharmazeutische zusammensetzungen
NZ220539A (en) 1,4-dihydropyridine derivatives and pharmaceutical compositions
AU609435B2 (en) Prevention of bovine respiratory disease complex in cattle by administration of interferon
KR970701559A (ko) 펩타이드의 경구 투여를 위한 안정화된 조성물(stabilized composition for oral administration of peptides)
IT1238210B (it) Esteri del cefamandolo nafato, procedimento per la loro preparazione erelative composizioni farmaceutiche.
FR2722500B1 (fr) Derives d'acide 2-thienylimidazo(1,2-a) benzimidazole-3-acetique, leur preparation et leur application en therapeutique
RU96104616A (ru) Пептид, обладающий влиянием на регенерацию кроветворной и иммунной систем, и фармацевтическая композиция на его основе
IT208775Z2 (it) Siringa per l'anestesia intraligamentosa.